Product Information
DOXEPIN HCL 3 MG TABLET is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $1.3334 per EA under NDC 72205005230. Its NADAC has been published 165 times since Aug 9, 2023.
FDA first approved this application on Apr 3, 2023. Its Orange Book therapeutic-equivalence code is BX.
Strength
3 mg/1
Manufacturer
Novadoz Pharmaceuticals LLCNDC
72205005230
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXEPIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214823FDA Approved
4/3/2023
TE Code
BX
On Market Since
4/5/2023
Pharmacological Classes
Price Statistics
The NADAC for DOXEPIN HCL 3 MG TABLET has been published 165 times since Aug 9, 2023, and over the history we have for it it has declined 82.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3334 per EA |
|---|---|
| All-time high | $8.1473 (Sep 13, 2023) |
| All-time low | $1.3271 (Jul 22, 2026) |
| 52-week high | $2.1099 |
| 52-week low | $1.3271 |
| Median price | $2.6429 |
| Average price | $3.1102 |
| Largest weekly change | -32.6% (Sep 20, 2023) |
| Weeks tracked | 165 |
| Tracking since | Aug 9, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Doxepin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novadoz Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Doxepin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXEPIN HCL 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DOXEPIN HCL 3 MG TABLET, manufactured by Novadoz Pharmaceuticals LLC, is $1.3334 per EA (NDC 72205005230), effective Sep 30, 2026.
How has the price of DOXEPIN HCL 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for DOXEPIN HCL 3 MG TABLET has declined 82.9%. It has been tracked across 165 weekly CMS publications since Aug 9, 2023.
What are the highest and lowest recorded NADAC prices for DOXEPIN HCL 3 MG TABLET?
Since Aug 9, 2023, the NADAC for DOXEPIN HCL 3 MG TABLET has ranged from a low of $1.3271 (Jul 22, 2026) to a high of $8.1473 (Sep 13, 2023), with a median of $2.6429 per EA.
Are there cheaper alternatives to DOXEPIN HCL 3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DOXEPIN HCL 3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXEPIN HCL 3 MG TABLET?
DOXEPIN HCL 3 MG TABLET (NDC 72205005230) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.